ReportWire

Tag: personal care products

  • Family Dollar recalls dozens of P&G, J&J, Colgate products in 23 states due to incorrect temperature storage

    Family Dollar recalls dozens of P&G, J&J, Colgate products in 23 states due to incorrect temperature storage

    [ad_1]

    Family Dollar voluntarily recalled dozens of over-the-counter drugs, products and medical devices sold at its stores because they had been stored at improper temperatures, according to the Food and Drug Administration late Tuesday.

    On the FDA’s website, the regulator said products affected by the recall were stored “outside of labeled temperature requirements by Family Dollar and inadvertently shipped to certain stores on or around June 1, 2023 through September 21, 2023.”

    Brands affected by the recall include Procter & Gamble’s
    PG,
    +0.99%

    Crest, Vicks and Pepto Bismol; Colgate
    CL,
    +0.26%

    ; Johnson & Johnson Inc.’s
    JNJ,
    -0.11%

    Tylenol and Listerine; and Bayer’s
    BAYN,
    +3.04%

    Aleve, according to a list provided by the FDA.

    The items were sold at stores in Alabama, Arkansas, Arizona, California, Colorado, Florida, Georgia, Idaho, Kansas, Louisiana, Mississippi, Montana, North Dakota, Nebraska, New Mexico, Nevada, Oklahoma, Oregon, South Dakota, Texas, Utah, Washington and Wyoming, between June 1 and Oct. 4, the FDA said.

    Family Dollar was acquired by Dollar Tree Inc.
    DLTR,
    +3.26%

    in a deal that closed in July 2015.

    [ad_2]

    Source link

  • Instacart, Ford, Pinterest, Coty, Dollar General, Intel, and More Stock Market Movers

    Instacart, Ford, Pinterest, Coty, Dollar General, Intel, and More Stock Market Movers

    [ad_1]


    • Order Reprints
    • Print Article
    [ad_2]
    Source link

  • J&J Dividend Decision Shows Power of Free Cash Flow

    J&J Dividend Decision Shows Power of Free Cash Flow

    [ad_1]


    • Order Reprints

    • Print Article



    Johnson & Johnson


    plans to maintain its quarterly dividend at $1.19 a share even after separating its


    Kenvue


    over-the-counter drug and pers…

    [ad_2]

    Source link

  • Johnson & Johnson Maintains Dividend After Kenvue Spinout

    Johnson & Johnson Maintains Dividend After Kenvue Spinout

    [ad_1]



    Johnson & Johnson


    on Wednesday issued new financial guidance after spinning out the consumer-health company


    Kenvue


    While its earnings and sales projections were lowered on an absolute basis, the company is maintaining its dividend and expects to increase its revenue at a faster pace.

    [ad_2]

    Source link

  • J&J Investors Can Convert Only a Fraction of Shares Into Kenvue Stock

    J&J Investors Can Convert Only a Fraction of Shares Into Kenvue Stock

    [ad_1]



    Johnson & Johnson


    $35 billion exchange offer for


    Kenvue


    that expired last Friday was substantially oversubscribed. The result is that participating J&J holders will be able to convert only a fraction of their shares for Kenvue stock.

    [ad_2]

    Source link

  • J&J’s Kenvue Deal Could Be Too Popular. What Happens if It Is.

    J&J’s Kenvue Deal Could Be Too Popular. What Happens if It Is.

    [ad_1]



    Johnson and Johnson


    $40 billion exchange offer for shares in


    Kenvue


    is likely to generate strong interest from the healthcare company’s shareholders, resulting in participants being able to swap only a portion of their J&J stock. 

    [ad_2]

    Source link

  • J&J Investors Must Decide If They Want Kenvue Stock

    J&J Investors Must Decide If They Want Kenvue Stock

    [ad_1]


    • Order Reprints

    • Print Article

    [ad_2]

    Source link

  • Like choosy shoppers at a retail store, IPO investors are demanding discounts and displaying price sensitivity

    Like choosy shoppers at a retail store, IPO investors are demanding discounts and displaying price sensitivity

    [ad_1]

    IPO investors, much like retail shoppers in recent years’ inflationary environment, are demanding clear discounts and demonstrating sensitivity to price and valuations, according to Renaissance Capital.

    The provider of IPO exchange-traded funds and institutional research said that’s a positive — even if tech unicorns in the pipeline would prefer it were not the case.

    “Quality consumer names are working,” said Matthew Kennedy, senior strategist at Renaissance, listing Kenvue, Cava Group Inc., Gen Restaurant Group Inc. and Savers Value Village Inc. as examples of recent new issues that enjoyed strong debuts.

    Kenvue
    KVUE,
    +1.65%
    ,
    the former consumer arm of Johnson & Johnson
    JNJ,
    +0.87%

    and parent of household-name products such as Tylenol and Band-Aid, raised $3.8 billion in its May IPO at a valuation of $41.08 billion, making it the biggest deal of the year to date.

    Cava Group
    CAVA,
    -5.93%
    ,
    the loss-making Mediterranean-style fast-casual restaurant group, raised $317 million in its mid-June deal at a valuation of $2.5 billion. The stock popped more than 99% on its first day of trade.

    For more: Cava Group CFO is confident restaurant chain will be profitable — but she won’t say when

    Gen Restaurant Group
    GENK,
    +13.95%

    is a profitable Korean barbecue chain that made its debut Wednesday with a more than 50% pop in early trade.

    “But broadly investors are still demanding clear discounts to public peers, especially if they take issue with certain aspects of a deal. So it’s good to see that valuation sensitivity,” said Kennedy.

    Savers Value Village
    SVV,
    +3.45%

    went public Thursday with some fanfare, closing 27% above its $18 issue price. The company is the biggest for-profit thrift-store chain in North America, with 317 stores that operate under multiple names.

    The company is profitable, with net income of $11.9 million in the quarter through April 2, after a loss of $10.2 million in the same period a year earlier. For all of 2022, it had net income of $84.7 million, up from $83.4 million in 2021.

    Revenue for the quarter came to $327.5 million, down from $345.7 million in the year-ago period. Revenue totaled $1.4 billion for 2022, up from $1.2 billion in 2021.

    See: Money-losing food chain Cava showed IPO success. Is it finally time for some tech deals?

    Two other deals that made their debut on Thursday fared less well, however.

    Texas-based Kodiak Gas Services Inc. 
    KGS,
    +3.44%

     and Fidelis Insurance Holdings Ltd. closed lower after pricing below their estimated ranges and making other accommodations to get their deals through.

    Bermuda-based Fidelis, a reinsurer, downsized its deal to 15 million shares from a previous expectation that it would offer 17 million. The initial public offering was priced at $14 a share, below the proposed $16-to-$19 range.

    Maker of oil- and gas-production equipment Kodiak opened almost 3% below its issue price of $16, which was well below its proposed price range of $19 to $22.

    Fidelis has an unusual structure, in that it uses a third party for origination, underwriting and claims management, said Kennedy.

    “We think insurance investors wanted a discount for a company that didn’t own the underwriting group,” he said. “It has an experienced management team, though, so now they’ll just need to execute.”

    Kodiak, meanwhile, carries substantial debt and will need to undertake significant capital spendig in the coming years, just as gas prices have fallen back.

    It’s also worth noting that the last big oil and gas IPO, Atlas, “is slightly below its offer price,” Kennedy said.

    Atlas Energy Solutions Inc.
    AESI,
    -2.75%

    went public in March at an issue price of $18 a share. The stock was last quoted at $17.52.

    Still, Renaissance is expecting a gradual reopening of the IPO market in the second half, said Kennedy, who noted that the IPO ETF
    IPO,
    +1.38%

    has gained about 30% in to date in 2023, outperforming the S&P 500’s
    SPX,
    +1.23%

    14% gain.

    To date, there have been 52 IPOs this year, up 33% from the same time last year, when the market was effectively frozen. Almost $9 billion in proceeds have been raised, up 115% from last year but well below levels seen in frothier times.

    [ad_2]

    Source link

  • P&G Earnings Hit By Higher Costs. ‘Strength in Innovation’ May Help Demand.

    P&G Earnings Hit By Higher Costs. ‘Strength in Innovation’ May Help Demand.

    [ad_1]



    Procter & Gamble


    stock recovered from an early loss, edging higher after the consumer goods company posted second-quarter earnings that matched analysts’ expectations. Gross margins declined largely due to higher costs.

    Net sales came in at $20.8 billion, while diluted earnings were $1.59 per share, Procter & Gamble said Thursday. Analysts had anticipated $20.7 billion of sales and a per-share profit of $1.59, according to FactSet.

    [ad_2]

    Source link